keyword
MENU ▼
Read by QxMD icon Read
search

infliximab and methotrexate

keyword
https://www.readbyqxmd.com/read/29760546/thiopurines-are-negatively-associated-with-anthropometric-parameters-in-pediatric-crohn-s-disease
#1
Neera Gupta, Robert H Lustig, Cewin Chao, Eric Vittinghoff, Howard Andrews, Cheng-Shiun Leu
AIM: To determine the distribution of anthropometric parameter (AP)- z -scores and characterize associations between medications/serum biomarkers and AP- z -scores in pediatric Crohn's disease (CD). METHODS: CD patients [< chronological age (CA) 21 years] were enrolled in a cross-sectional study. Descriptive statistics were generated for participants' demographic characteristics and key variables of interest. Paired t -tests were used to compare AP- z -scores calculated based on CA (CA z -scores) and bone age (BA) (BA z -scores) for interpretation of AP's...
May 14, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29750443/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-update-short-version-part-1-systemic-treatment
#2
Alexander Nast, Lasse Amelunxen, Matthias Augustin, Wolf-Henning Boehncke, Corinna Dressler, Matthew Gaskins, Peter Härle, Bernd Hoffstadt, Joachim Klaus, Joachim Koza, Ulrich Mrowietz, Hans-Michael Ockenfels, Sandra Philipp, Kristian Reich, Thomas Rosenbach, Berthold Rzany, Martin Schlaeger, Gerhard Schmid-Ott, Michael Sebastian, Ralph von Kiedrowski, Tobias Weberschock
The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. The guideline is based on a systematic literature review completed on December 1, 2016, and on a formal consensus and approval process. The first section of this short version of the guideline covers systemic treatment options considered relevant by the expert panel and approved in Germany at the time of the consensus conference (acitretin, adalimumab, apremilast, cyclosporine, etanercept, fumaric acid esters, infliximab, methotrexate, secukinumab and ustekinumab)...
May 2018: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/29731461/-diagnosis-and-treatment-of-rheumatoid-arthritis-toward-the-best-practice-the-best-practice-for-tnf-inhibitors
#3
Hideto Kameda
As of February 2018, 5 originator TNF inhibitors(infliximab, etanercept, adalimumab, golimumab and certolizumab pegol)and biosimilar agents of infliximab and etanercept are available for rheumatoid arthritis(RA)in Japan. The effectiveness of TNF inhibitors considerably improves with concomitant methotrexate regardless of their immunogenicity. The Japan College of Rheumatology guideline for TNF inhibitor use in RA has been updated in March 2017 according to recent evidences. During the remission induction phase, maintenance of drug trough level above effective blood concentration is paramount, while the tapering and withdrawal of TNF inhibitors may be considered after achieving sustained remission...
2018: Clinical Calcium
https://www.readbyqxmd.com/read/29729105/cost-effectiveness-of-secukinumab-as-first-biologic-treatment-compared-with-other-biologics-for-moderate-to-severe-psoriasis-in-germany
#4
Matthias Augustin, Doreen McBride, Isabelle Gilloteau, Caitriona O'Neill, Katja Neidhardt, Christopher N Graham
BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, has demonstrated strong and sustained efficacy in adults with moderate to severe psoriasis in clinical trials. OBJECTIVE: This analysis compared the cost per responder of secukinumab as first biologic treatment of moderate to severe psoriasis, with adalimumab, infliximab, etanercept, and ustekinumab in Germany. METHODS: A 52-week decision-tree model was developed...
May 5, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29718278/the-impact-of-combination-therapy-on-infliximab-levels-and-antibodies-in-children-and-young-adults-with-inflammatory-bowel-disease
#5
Lisa Yue Chi, Naamah Levy Zitomersky, Enju Liu, Sophia Tollefson, Julia Bender-Stern, Snehal Naik, Scott Snapper, Athos Bousvaros
Goal: The aim of this study was to evaluate the effect of combination therapy with methotrexate or 6-mercaptopurine on infliximab levels (IFXL) and antibodies to infliximab (ATI). Background: Infliximab (IFX) is a highly effective therapy for inflammatory bowel disease (IBD). Unfortunately, 25%-50% of patients will lose response to IFX. Loss of response is correlated with low IFXL and ATI formation which accelerates drug clearance. Combination therapy is thought to decrease ATI formation...
April 26, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29671942/comparative-efficacy-and-safety-of-biosimilar-infliximab-and-originator-infliximab-in-combination-with-methotrexate-in-patients-with-active-rheumatoid-arthritis-a-meta-analysis-of-randomized-controlled-trials
#6
Sang-Cheol Bae, Young Ho Lee
OBJECTIVE: We aimed to assess the relative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate (MTX) compared to placebo plus MTX in active rheumatoid arthritis (RA). METHODS: We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) examining the efficacy and safety of biosimilar + MTX and infliximab + MTX and placebo + MTX (MTX group) in patients with active RA despite treatment with MTX...
April 19, 2018: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29618976/the-efficacy-and-safety-of-mainstream-medications-for-patients-with-cdmard-na%C3%A3-ve-rheumatoid-arthritis-a-network-meta-analysis
#7
Weiyan Cai, Youyi Gu, Huanqin Cui, Yinyin Cao, Xiaoliang Wang, Yi Yao, Mingyu Wang
Background: The mainstream medications for rheumatoid arthritis (RA) include conventional disease-modifying antirheumatic drugs (cDMARDs), which mostly are methotrexate (MTX), and biologic agents such as adalimumab (ADA), certolizumab (CZP), etanercept (ETN), golimumab (GOL), infliximab (IFX), and tocilizumab (TCZ). This network meta-analysis was aimed at evaluating the efficacy and safety of the medications above and interventions combining cDMARDs and biologic agents for patients with RA. Methods: PubMed, EMBASE, Cochrane Library, and ClinicalTrials...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29610003/-therapeutic-strategy-for-the-treatment-of-non-infectious-uveitis-proposed-by-an-expert-panel
#8
E Diwo, P Sève, S Trad, P Bielefeld, D Sène, S Abad, A Brézin, P Quartier, I Koné Paut, M Weber, C Chiquet, M H Errera, J Sellam, P Cacoub, G Kaplanski, L Kodjikian, B Bodaghi, D Saadoun
Conventional immunosuppressive drugs, anti-TNF alpha and other biotherapies used in clinical practice are capable of controlling non-infectious anterior uveitis, posterior uveitis and panuveitis. The present work has been led by a multidisciplinary panel of experts, internists, rheumatologists and ophthalmologists and is based on a review of the literature. In case of corticodependency or sight-threatening disease, conventional immunosuppressive drugs (methotrexate, azathioprine and mycophenolate mofetil) and/or anti-TNF alpha (adalimumab, infliximab) are used to achieve and maintain remission...
March 30, 2018: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/29601563/-advances-in-differential-diagnosis-and-treatment-of-patients-with-sarcoidosis
#9
REVIEW
Tadeusz Płusa
The implementation of treatment in patients with sarcoidosis (SA) must be associated with the certainty of diagnosis, which is difficult due to the lack of unambiguous criteria. Finding the presence of noncaseating granulomas in bioptic material is not always indicative of SA. The main point of SA's diagnosis is the level of its activity, because only patients in the active stage should be qualified for treatment. In therapy, glucocorticosteroids or second-line drugs - methotrexate or azathioprine are still recommended...
March 27, 2018: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29600931/effects-of-biologic-disease-modifying-anti-rheumatic-drugs-on-the-radiographic-progression-of-rheumatoid-arthritis-a-systematic-literature-review
#10
REVIEW
Bernard Combe, Sadiq Lula, Caroline Boone, Patrick Durez
OBJECTIVES: To evaluate the effect of biologic disease-modifying anti-rheumatic drugs (bDMARDs) on radiographic progression in patients with rheumatoid arthritis (RA). METHODS: A systematic review of electronic databases and conference proceedings was conducted through January 2015, to identify randomised controlled trials (RCTs) and observational studies that assessed the impact of bDMARDs [± conventional synthetic DMARDs (csDMARDs), mainly methotrexate (MTX)], versus csDMARDs alone, on radiographic progression in patients with RA...
March 20, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29594973/clinical-and-therapeutic-aspects-of-linear-psoriasis-a-study-of-30-cases
#11
Matthieu Say, Franck Boralévi, Cédric Lenormand, Anne-Claire Bursztejn, Eric Estève, Alice Phan, Emmanuelle Bourrat, Jean-Philippe Lacour, Marie-Aleth Richard, Aurélie Acher, Denis Jullien, Nathalie Beneton, Vincent Descamps, Christine Bodemer, Marion Lagaude, Christine Chiaverini, Emmanuel Mahé
BACKGROUND: Psoriasis affects 2-4% of the population, with the most common clinical type being plaque psoriasis. The linear form of psoriasis is very rare. The literature on linear psoriasis (LP) consists of only case reports, and data are few. OBJECTIVE: This study aimed to better understand LP in a large-scale study. PATIENTS AND METHODS: We retrospectively retrieved the medical records from 14 French medical centers of patients newly diagnosed clinically with LP, with or without the support of histology, between 1 February and 31 July 2015...
March 29, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29562275/risk-of-serious-bacterial-infection-associated-with-tumor-necrosis-factor-alpha-inhibitors-in-children-and-young-adults-with-inflammatory-bowel-disease
#12
Wan-Ju Lee, Todd A Lee, Gregory S Calip, Katie J Suda, Leslie Briars, Glen T Schumock
Background: Prior studies evaluating the relationship between tumor necrosis factor-alpha inhibitors (TNFI) and infection were conducted in adults and had conflicting findings. We sought to examine the risk of serious infection associated with TNFIs compared with nonbiologic immunomodulators in children and young adults with inflammatory bowel disease (IBD) and to compare the risk among individual TNFIs. Methods: We conducted a cohort study using the Truven MarketScan Commercial Claims and Encounters database of patients age <30 years with a diagnosis of IBD who initiated treatment with a TNFI or immunomodulator (thiopurines or methotrexate) between 2009 and 2013...
March 19, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29543846/drug-retention-and-discontinuation-reasons-between-seven-biologics-in-patients-with-rheumatoid-arthritis-the-answer-cohort-study
#13
Kosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, Akira Ohnishi, Daijiro Kabata, Toru Hirano, Ryota Hara, Masaki Katayama, Shuzo Yoshida, Koji Nagai, Yonsu Son, Hideki Amuro, Kengo Akashi, Takanori Fujimura, Makoto Hirao, Keiichi Yamamoto, Ayumi Shintani, Atsushi Kumanogoh, Hideki Yoshikawa
The purpose of this study was to evaluate the retention and discontinuation reasons of seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting of patients with rheumatoid arthritis (RA). 1,037 treatment courses with bDMARDs from 2009 to 2016 [female, 81.8%; baseline age, 59.6 y; disease duration 7.8 y; rheumatoid factor positivity 81.5%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate (DAS28-ESR), 4.4; concomitant prednisolone 43.5% and methotrexate 68...
2018: PloS One
https://www.readbyqxmd.com/read/29538028/adalimumab-induced-epstein-barr-virus-related-lymphoproliferative-disorder-on-fdg-pet-ct
#14
John Ward, Ariela Noy, Gary Ulaner, Christopher Riedl
Adalimumab is a fully human chimeric tumor necrosis factor inhibitor used to treat immune-mediated disorders such as psoriatic arthritis. We present a 51-year-old woman with psoriatic arthritis on methotrexate and infliximab for 12 years. Adalimumab replaced infliximab because of worsening symptoms. Following 3 doses administered 1 week apart, rapidly enlarging cervical lymph nodes developed. Biopsy revealed Epstein-Barr virus-related polymorphic lymphoproliferative disorder. F-FDG PET/CT demonstrated widespread hypermetabolic lymphadenopathy; follow-up at 5 weeks off adalimumab revealed almost complete resolution of this adenopathy...
March 13, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29531640/blood-glucose-changes-surrounding-initiation-of-tumor-necrosis-factor-inhibitors-and-conventional-disease-modifying-anti-rheumatic-drugs-in-veterans-with-rheumatoid-arthritis
#15
Patrick R Wood, Evan Manning, Joshua F Baker, Bryant England, Lisa Davis, Grant W Cannon, Ted R Mikuls, Liron Caplan
AIM: To determine the scope of acute hypoglycemic effects for certain anti-rheumatic medications in a large retrospective observational study. METHODS: Patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry were selected who, during follow-up, initiated treatment with tumor necrosis factor inhibitors (TNFi's, including etanercept, adalimumab, infliximab, golimumab, or certolizumab), prednisone, or conventional disease-modifying anti-rheumatic drugs (DMARDs), and for whom proximate random blood glucose (RBG) measurements were available within a window 2-wk prior to, and 6 mo following, medication initiation...
February 15, 2018: World Journal of Diabetes
https://www.readbyqxmd.com/read/29529104/psoriasis-treatment-in-hiv-positive-patients-a-systematic-review-of-systemic-immunosuppressive-therapies
#16
Mio Nakamura, Michael Abrouk, Benjamin Farahnik, Tian H Zhu, Tina Bhutani
The management of psoriatic disease in the human immunodeficiency virus (HIV)-positive population is challenging. The clinical course often is progressive and refractory; therefore, first- and second-line therapies including topical agents, phototherapy, and oral retinoids often are inadequate. Most other currently available systemic therapies for psoriatic disease are immunosuppressive, which poses a distinct clinical challenge. A comprehensive systematic review of the literature via a PubMed search of articles indexed for MEDLINE using the terms psoriasis and HIV and psoriatic arthritis and HIV combined with several systemic immunosuppressive agents yielded a total of 25 reported cases of systemic immunosuppressive therapies used to treat psoriatic disease in HIV-positive patients including methotrexate, cyclosporine, etanercept, adalimumab, infliximab, and ustekinumab...
January 2018: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/29488599/-pneumocystis-jiroveci-pneumonia-following-infliximab-therapy-in-patient-with-crohn-s-disease
#17
Daniela Fluxá, Jorge Segovia, Matías Florenzano, Jessica Salinas, Lilian Flores, Daniela Simian, Rodrigo Quera
There are no evidence-based guidelines about prophylaxis against Pneumocystis jiroveci pneumonia in inflammatory bowel disease. We report a case of P. jiroveci pneumonia in patient with Crohn's disease receiving infliximab and methotrexate. This case emphasizes the importance of considering the possibility of this infection in inflammatory bowel disease patients treated on biological therapy.
October 2017: Revista Chilena de Infectología: órgano Oficial de la Sociedad Chilena de Infectología
https://www.readbyqxmd.com/read/29464314/activation-status-of-peripheral-blood-neutrophils-and-the-complement-system-in-adult-rheumatoid-arthritis-patients-undergoing-combined-therapy-with-infliximab-and-methotrexate
#18
Larissa F Marchi, Adriana B Paoliello-Paschoalato, Renê D R Oliveira, Ana Elisa C S Azzolini, Luciana M Kabeya, Eduardo A Donadi, Yara Maria Lucisano-Valim
We examined the functional activity of peripheral blood neutrophils and the complement system activation status in patients with rheumatoid arthritis (RA) undergoing infliximab/methotrexate combined therapy. We studied female RA patients under treatment with infliximab (3-5 mg/kg) and methotrexate (15-25 mg/week) who presented inactive (i-RA; n = 34, DAS-28 ≤ 2.6) or at least moderately active disease (a-RA; n = 29, DAS-28 > 3.2), and age-matched healthy women (n = 38). We measured the levels of reactive oxygen species (ROS) generation (chemiluminescence assay) and membrane expression of FcγRIIa/CD32, FcγRIIIb/CD16, CR1/CD35, and CR3/CD11b receptors (ELISA assay) in neutrophils...
June 2018: Rheumatology International
https://www.readbyqxmd.com/read/29462391/combination-immunosuppression-in-ibd
#19
Steven Bots, Krisztina Gecse, Murray Barclay, Geert D'Haens
Whether to use biologic treatment for inflammatory bowel disease as monotherapy or in combination with immunosuppressives has been a matter of debate in the last 2 decades. Combination therapy was not superior in any of the registration trials for Crohn's disease and ulcerative colitis for TNF antagonists, vedolizumab, or ustekinumab. It needs to be mentioned, though, that none of these trials were powered to detect such differences, and that many patients entered the trial after having failed conventional immunosuppressives...
February 15, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29461286/recent-advances-in-the-treatment-of-rheumatoid-arthritis
#20
Tina D Mahajan, Ted R Mikuls
PURPOSE OF REVIEW: Therapies for rheumatoid arthritis (RA) continue to expand rapidly. The purpose of this review is to discuss novel treatment options, including biosimilars, that are available, as well as to highlight promising agents in development. The purpose is also to discuss new emerging safety signals associated with these drugs and to discuss strategies in tapering therapy. RECENT FINDINGS: There are several novel RA therapies. These include the interleukin-6 (IL-6) receptor blocker sarilumab, which was approved in 2017...
May 2018: Current Opinion in Rheumatology
keyword
keyword
25859
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"